Evaluating hemoptysis hospitalizations among patients with bronchiectasis in the United States: a population-based cohort study
Authors:
Open Access
- 1 December 2021
- journal article
- research article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 21 (1) , 1-8
Abstract
Background: The burden of hospitalizations and mortality for hemoptysis due to bronchiectasis is not well characterized. The primary outcome of our study was to evaluate in-hospital mortality in patients admitted with hemoptysis and bronchiectasis, as well as the rates of bronchial artery embolization, length of stay, and hospitalization costs. Methods: The authors queried the Nationwide Inpatient Sample (NIS) claims database for hospitalizations between 2016 and 2017 using the ICD-10-CM codes for hemoptysis and bronchiectasis in the United States. Multivariable regression was used to evaluate predictors of in-hospital mortality, embolization, length of stay, and hospital costs. Results: There were 8240 hospitalizations (weighted) for hemoptysis in the United States from 2016 to 2017. The overall in-hospital mortality was 4.5%, but higher in males compared to females. Predictors of in-hospital mortality included undergoing three or more procedures, age, and congestive heart failure. Bronchial artery embolization (BAE) was utilized during 2.1% of hospitalizations and was more frequently used in those with nontuberculous mycobacteria and aspergillus infections, but not pseudomonal infections. The mean length of stay was 6 days and the median hospitalization cost per patient was USD $9,610. Having comorbidities and procedures was significantly associated with increased length of stay and costs. Conclusion: Hemoptysis is a frequent indication for hospitalization among the bronchiectasis population. In-hospital death occurred in approximately 4.5% of hospitalizations. The effectiveness of BAE in treating and preventing recurrent hemoptysis from bronchiectasis needs to be explored.Keywords
This publication has 33 references indexed in Scilit:
- Moderate hemoptysis: recurrent hemoptysis and mortality according to bronchial artery embolizationThe Clinical Respiratory Journal, 2014
- Non–Cystic Fibrosis BronchiectasisAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trialThorax, 2013
- Effect of Long-term, Low-Dose Erythromycin on Pulmonary Exacerbations Among Patients With Non–Cystic Fibrosis BronchiectasisJAMA, 2013
- Effect of Azithromycin Maintenance Treatment on Infectious Exacerbations Among Patients With Non–Cystic Fibrosis BronchiectasisJAMA, 2013
- Predictors of mortality in hospitalized patients with acute exacerbation of bronchiectasisRespiratory Medicine, 2010
- Survival of bronchiectatic patients with respiratory failure in ICUBMC Pulmonary Medicine, 2007
- Characterisation of the onset and presenting clinical features of adult bronchiectasisRespiratory Medicine, 2006
- Prevalence and Economic Burden of BronchiectasisClinical Pulmonary Medicine, 2005
- Survival of Patients With Bronchiectasis After the First ICU Stay for Respiratory FailureChest, 2004